Vandria reports VNA-318’s first-in-human data in Alzheimer’s

Vandria has taken a step forward in its bid to bring a new kind of Alzheimer’s treatment into the clinic. The Lausanne-based company shared first-in-human data for its lead candidate VNA-318 ahead of its presentation at the Clinical Trials on…